Non-hepatic metabolism. Temozolomide lacks CYP-affinity. Side effects as nausea, anorexia and vomiting may be potentially porphyrinogenic through reduction in caloric intake.

Triazene derivative.

Temozolomide is an alkylating antineoplastic agent used to treat newly diagnosed glioblastoma multiforme, recidivating or therapy resistent malignant glioma and refractory anaplastic astrocytoma. Given orally in combination with radiation therapy. Common adverse reactions of temozolomide that can be confused with an acute porphyric attack are nausea, vomiting, obstipation, myopathy, paraesthesia.

Not significant

Rapid nonenzymatic hydrolysis hydrolysis at physiological pH to metabolites that undergo renal excretion. Distributed to brain giving rise to cytotoxic metabolites via spontaneous hydrolysis, where metabolites undergo renal clearence.

No.